Ronald C. Renaud JR - Sep 14, 2021 Form 4 Insider Report for Translate Bio, Inc. (TBIO)

Role: Chief Executive Officer, Director
Signature: /s/ Paul D. Burgess, as attorney-in-fact for Ronald C. Renaud, Jr.
Stock symbol: TBIO
Transactions as of: Sep 14, 2021
Transactions value $: -$36,254,014
Form type: 4
Date filed: 9/14/2021, 07:32 PM
Previous filing: Jun 9, 2021
Next filing: Dec 23, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBIO	Common Stock	Sale	-$19.1M	-503K	-100%	$38.00^*	0	Sep 14, 2021	Direct	F1
transaction	TBIO	Common Stock	Sale	-$15.6M	-410K	-100%	$38.00^*	0	Sep 14, 2021	By Ronald Renaud 2014 Irrevocable Family Trust	F1
transaction	TBIO	Common Stock	Sale	-$1.55M	-40.9K	-100%	$38.00^*	0	Sep 14, 2021	By Ronald C. Renaud, Jr. Trust - 2007	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-500K	-100%	$0.00^*	0	Sep 14, 2021	Common Stock	500K	$7.95	Direct	F2, F3
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-525K	-100%	$0.00^*	0	Sep 14, 2021	Common Stock	525K	$7.66	Direct	F2, F4
transaction	TBIO	Stcok Option (right to buy)	Sale	$0	-325K	-100%	$0.00^*	0	Sep 14, 2021	Common Stock	325K	$23.82	Direct	F2, F5
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-1.07M	-100%	$0.00^*	0	Sep 14, 2021	Common Stock	1.07M	$7.39	Direct	F2, F6
transaction	TBIO	Stock Option (right to buy)	Sale	$0	-90K	-100%	$0.00^*	0	Sep 14, 2021	Common Stock	90K	$8.34	Direct	F2, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
F2	Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F3	This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
F4	This option was granted on March 3, 2020. This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.
F5	This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 9, 2025.
F6	This option was granted on December 22, 2017. The shares underlying became fully vested on March 9, 2021.
F7	This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.